Novartis profits dip as generic rival challenges cancer drug

Thursday, April 21, 2016 - 02:40 in Mathematics & Economics

GENEVA (AP) -- Swiss pharmaceuticals titan Novartis says net income from continued operations fell 13 percent in the first quarter as generic competition cut into sales of Gleevec, one of the first very effective cancer medicines....

Read the whole article on AP Health

More from AP Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net